Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants
Erkens, Remco G. A., Calis, Jorg J. A., Verwoerd, Anouk, De Roock, Sytze, Ter Haar, Nienke M., Den Engelsman, Gerda, Van der Veken, Lars T., Ernst, Robert F., Van Deutekom, Hanneke W. M., Pickering, Alex, Scholman, Rianne C., Jansen, Marc H. A., Swart, Joost F., Sinha, Rashmi, Roth, Johannes, Schulert, Grant S., Grom, Alexei A., Van Loosdregt, Jorg, Vastert, Sebastiaan J.
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2024)
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.01.2024)
Get full text
Journal Article